KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to -$257.5 million.

  • Pacira BioSciences' Cash from Financing Activities fell 8950.12% to -$257.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.9 million, marking a year-over-year decrease of 1924.11%. This contributed to the annual value of $17.4 million for FY2024, which is 109.49% up from last year.
  • Per Pacira BioSciences' latest filing, its Cash from Financing Activities stood at -$257.5 million for Q3 2025, which was down 347.75% from -$57.5 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Cash from Financing Activities high stood at $361.4 million for Q4 2021, and its period low was -$257.5 million during Q3 2025.
  • Over the past 3 years, Pacira BioSciences' median Cash from Financing Activities value was -$2.8 million (recorded in 2024), while the average stood at -$44.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 5,577.27% in 2024, then crashed by 8,950.12% in 2025.
  • Pacira BioSciences' Cash from Financing Activities (Quarterly) stood at $361.4 million in 2021, then slumped by 116.19% to -$58.5 million in 2022, then spiked by 96.96% to -$1.8 million in 2023, then decreased by 9.89% to -$2.0 million in 2024, then crashed by 8,950.12% to -$257.5 million in 2025.
  • Its last three reported values are -$257.5 million in Q3 2025, -$57.5 million for Q2 2025, and -$3.0 million during Q1 2025.